1 / 9

Adalimumab: Lymphomas

Presented at the Arthritis Advisory Committee meeting on March 4, 2003 by Jeffrey N. Siegel, M.D. Adalimumab: Lymphomas. Controlled portions of controlled trials: Adalimumab: 2 cases among 1380 patients, 0.6 yrs mean exposure Placebo: 0 cases among 690 patients, 0.5 yrs mean exposure

ivria
Download Presentation

Adalimumab: Lymphomas

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Presented at the Arthritis Advisory Committee meeting on March 4, 2003 by Jeffrey N. Siegel, M.D.

  2. Adalimumab: Lymphomas • Controlled portions of controlled trials: • Adalimumab: 2 cases among 1380 patients, 0.6 yrs mean exposure • Placebo: 0 cases among 690 patients, 0.5 yrs mean exposure • Overall database: 10 cases among 2400 patients, 2.4 yrs median exposure, SIR 5.42 (2.6, 10.0)

  3. Etanercept: Lymphomas • Controlled portions of controlled trials: • Etanercept: 1 case among 2502 patients, 0.5 yrs mean exposure • Placebo: 0 cases among 921 patients, 0.5 yrs mean exposure • Overall database: 6 cases among 3389 patients, 2.2 yrs mean exposure, SIR 2.31 (0.85, 5.03)

  4. Infliximab: Lymphomas • Controlled portions of controlled trials: • Infliximab: 3 cases among 2421 patients, 1.0 yrs mean exposure • Placebo: 0 cases among 489 patients, 0.9 yrs mean exposure • Overall database: 6 cases among 2421 patients, 1.7 yrs mean exposure, SIR 6.98 (2.56, 15.19)

  5. Concluding Remarks: Lymphomas • Newer data show occurrence of lymphomas with each of the approved agents: • In controlled trials, 1-3 cases with study drugs vs. 0 with placebo • Controlled plus non-controlled extension trials showed higher rate than in general US population • Additional cases in post-marketing experience • Higher reported rates in RA patients complicates analysis

  6. CHF • Deleterious effects of infliximab in CHF patients • Concerning trends in CHF patients receiving etanercept • Adalimumab – not known

  7. Conclusions • Approved TNF blockers associated with high ACR response rates in RA, beneficial effects in progression of structural damage • For infliximab, demonstrated improvement in HAQ in long-term study • A number of serious, but uncommon, adverse reactions also associated with their use • For some adverse events, risks can be reduced with appropriate screening

  8. Risk Management • Important to: • Maximize benefit • Minimize risk • For identified risks of TNF blockers: • Collect data to accurately assess risk • Minimize risks where appropriate by patient selection and screening • Risk communication

  9. Agency Welcomes Discussion of: • For lymphoma • Confounding factors in assessing causal relationships • Likelihood of causal relationship between lymphomas & TNF blockers • How to collect data that would help assess causal associations • Appropriate language for labels to communicate available information • For CHF • Approaches to risk management

More Related